Veterinary Allergy
Allergy (Veterinary)
Phase 2/Phase 3Active
Key Facts
About Genclis
Genclis is a biotechnology company pioneering a novel drug discovery and development platform based on Transcription Infidelity (TI), a biological mechanism that generates immunologically active variant proteins from mRNA. Its pipeline includes programs in veterinary and human allergies, severe COVID-19, Type 1 Diabetes, and Lou Gehrig's disease (ALS), with its veterinary allergy candidate appearing most advanced. The company is privately held, led by co-founder and CEO Bernard Bihain, and operates with a cautious, capital-efficient business model focused on robust preclinical de-risking before clinical advancement.
View full company profile